Mark Stolper - 07 Jan 2022 Form 4/A - Amendment Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Director
Signature
/s/ McDavid Stilwell, as Attorney-in-Fact for Mark Stolper
Issuer symbol
CHRS
Transactions as of
07 Jan 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
11 Feb 2022, 15:13:19 UTC
Date Of Original Report
10 Jan 2022
Previous filing
06 Jan 2022
Next filing
17 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Award $0 +27,000 $0.000000 27,000 07 Jan 2022 Common Stock 27,000 $14.67 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Form 4/A is being filed solely to correct a typographical error in the exercise price. Except as noted in this footnote, all other information as disclosed in the Reporting Person's original Form 4 was accurately reported.
F2 The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.